Finding long-lasting treatment options for mental health disorders, including addiction, is complicated and met with various challenges. The use of psychedelics in treatment is getting more attention as recent research suggests efficacious treatment outcomes in specific behavioral health disorders. A revolutionary approach to addiction recovery is gaining momentum, harnessing the transformative power of psychedelic substances to reshape the landscape of mental health treatment. This groundbreaking method, known as psychedelic therapy, is challenging conventional wisdom and offering new hope to those struggling with addiction. As we delve into this fascinating world, we’ll explore how these once-taboo substances are being repurposed to heal minds and transform lives.

Support Our Mission

• One of the most common fMRI tasks employed in addiction populations which measures neural responses to monetary reward processing, is the monetary incentive delay task (MIDT) (85); which has identified pathophysiological reward processing in individuals with addictions.
• It sounds counterintuitive to use psychedelic substances as a treatment for addiction recovery.
• So we’re closer than ever to integrating psychedelic therapy in mental health care systems.
• This question has arisen in other contexts, most notably in discussions around ongoing attempts to develop nonsubjective, or non-hallucinogenic, psychedelics – named as such for their lack of a characteristic “trip”.
• In addition, there are the ‘non-classic psychedelics’; ketamine, 3,4-methylenedioxymethamphetamine (MDMA) and ibogaine (from the Iboga plant).

In the 1990s the first study of the use of ketamine combined with therapy in the treatment of alcohol addiction took place in Russia. The study was non-randomized and allowed patients to choose between ketamine-psychedelic therapy (KPT) or conventional are psychedelics addictive treatment. It was found that in the patients given three doses of 2.5 mg/kg (intramuscular) ketamine combined with psychodynamic psychotherapy 66% (versus 24% in the control group) achieved abstinence over 12 months follow-up (27).

Addiction and Mental Health Resources

Addiction has been conceptualized as a multiple-neurotransmitter disorder with evidence of blunted dexamphetamine-induced endorphin release in patients with alcohol (169) and pathological gambling as assessed with [11C]carfentanil when compared with healthy controls (170). These findings are consistent with growing evidence that dysregulation in opiate tone is consistent across both substance use and behavioral addictions, in the absence of changes in receptor availability and thus may play an important role in the pathophysiology of addictions broadly. Hence, this could be used as a surrogate addiction molecular biomarker to assess the effects of psychedelic therapy. Behaviors elicited by individuals with addiction can be characterized as impulsive, which describes the lack of inhibitory control and manifests as non-premeditated action (108). Increases in trait impulsivity have been consistently found in individuals with addictions compared to healthy controls when using validated clinical impulsivity scales (109).

From the Lab to the Clinic: The Science Behind Psychedelic Therapy

• Marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment, and results remained positive at 3 and 6 months.16 As this was an open-label trial with no control condition, limited conclusions can be drawn about treatment efficacy.
• If we agree with Besser and Oishi that psychological richness can be valued per se, this would provide an additional reason for valuing certain psychedelic experiences.
• AA’s model has since become a blueprint for countless other recovery programs and support groups, proving the efficacy of a communal, step-based approach to overcoming addiction.
• It’s not clear if he remains in the position, and Journey Colab did not immediately respond to Business Insider’s request for comment on his involvement with the company.
• The only requirement for membership is a desire to recover from our addictive behaviors and/or an interest in psychedelics as an aid to our process of recovery.

The SN is comprised of structurally and functionally connected brain regions with cortical areas including the anterior insula and ACC, as well as subcortical and limbic structures such as the amygdala, VS and thalamus (130, 131). This network of regions is considered to support one’s socioemotional functions by integrating visceral and sensory information (132, 133), as well as playing an intrinsic role in directing one’s attention toward salient stimuli (134). Notably, there is a significant anatomical overlap between the SN and the mesocorticolimbic system, with recent preclinical work indicating that the firing of mesolimbic dopamine neurons may activate nodes of the salience network (135). That said, I have met people for whom the experiential aspects of psychedelics do seem to compel a psychological dependence.

Patient Care Network

This ban states that these drugs have “no evidence of medical value” (UNODC, 1971) and has heavily impacted “an otherwise promising development of a novel treatment paradigm in mental health” (31). Despite these restrictions, the collection of real-world evidence for the therapeutic use of psychedelics has continued, in the form of retrospective, observational and naturalistic studies. Importantly, such real-world evidence can complement lab-based RCTs by indicating an intervention’s effectiveness in a more ecologically valid fashion and with more external validity than formal clinical trials can provide (32). Further, this data allows for the assessment of patients with multiple morbidities, with doses tailored to their clinical needs, which subsequently provide researchers with novel insights into parameters to design future studies (32). Below we summarize the evidence from such studies in individuals with addiction using classic and non-classic psychedelics for therapeutic purposes and have summarized these findings in Table 1. In clinical trials with classic psychedelics like psilocybin, a high dose, monitored entheogenic experience with clinical support is being shown to help people break addictive relationships with substances like alcohol, tobacco, and cocaine.

Mood and Anxiety Disorders

As a result, he became perhaps the most visible proponent for Ibogaine treatment. “I don’t know that I had much business doing this, but I’m not sure I had any less business than anyone doing this at Johns Hopkins or NYU or any of the training programs around the country,” he says. More recently, PayPal Mafia member Peter Thiel funded a psychedelic therapies startup.

Treat addiction with psychedelics?

The Psychedelic Integration Scales: Tools for Measuring Psychedelic Integration Behaviors and Experiences

• Dimitri’s goal is to offer specialized treatment, tailored to an individual’s needs.
• In addition to the DMN, the SN has also been heavily implicated in the psychopathophysiology of addiction.
• The irony with the absolutism found in many 12-step groups is that Bill Wilson himself, the founder of Alcoholics Anonymous, used LSD and spoke of its benefits.